Research Article
Efficacy of Mecobalamin Tablets Combined with Troxerutin in the Treatment of NSCLC Chemotherapy-Induced Peripheral Neuropathy
Table 1
Baseline characteristics of the two groups in this study.
| | Control group (n = 60) | Research group (n = 60) | t/χ2 | |
| Gender (n) | Male | 39 | 38 | 0.036 | 0.749 | Female | 21 | 22 | | |
| Age (years) | 60.29 ± 5.38 | 60.04 ± 6.01 | 0.614 | 0.427 |
| BMI (kg/m2) | 22.67 ± 2.17 | 22.71 ± 2.24 | 0.725 | 0.305 | Karnofsky performance status (points) | 94.28 ± 7.41 | 94.88 ± 8.12 | 0.831 | 0.207 |
| TNM stage (n) | II | 18 | 20 | 0.154 | 0.695 | III–IV | 42 | 40 | | |
| Differentiation (n) | Low | 8 | 9 | 0.170 | 0.918 | Middle | 30 | 31 | | | High | 22 | 20 | | |
| Cancer type (n) | Adenocarcinoma | 35 | 38 | 0.315 | 0.575 | Squamous cell carcinoma | 25 | 22 | | |
| Previous treatment | Previous surgery | 41 | 39 | 0.150 | 0.699 | Previous radiation therapy | 6 | 7 | 0.086 | 0.769 | Previous targeted therapy | 5 | 4 | 0.120 | 0.729 |
|
|